- Assembly Biosciences Inc Extraordinary Shareholders Meeting TranscriptJan 31, 2024
- Assembly Biosciences Inc Partnership with Gilead Sciences Inc to Develop Next-Generation Antiviral Therapeutics Call TranscriptOct 17, 2023
- Assembly Biosciences Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 25, 2023
- Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call TranscriptAug 31, 2022
- Assembly Biosciences Inc IFNAR (Interferon-a Receptor Agonist) Research - Corporate Call TranscriptJul 26, 2022
- Assembly Biosciences Inc HBV/HDV Entry Inhibitor Research - Corporate Call TranscriptMar 31, 2022
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 20, 2021
- Assembly Biosciences Inc Earnings Call TranscriptFeb 25, 2021$66.36 (-1.95%)Earnings
- Assembly Biosciences, Inc. - Special Call TranscriptNov 05, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptJul 20, 2020
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptJun 11, 2020
- Assembly Biosciences Inc to Discuss HBV Portfolio Progress Call TranscriptMay 07, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptNov 11, 2019
- Assembly Biosciences, Inc Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 Call TranscriptApr 15, 2019
Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call Transcript
Good day, everyone. I'm John McHutchison, CEO of Assembly Bio, and I'd like to welcome you to the third and final in our series of planned webcasts for 2022, introducing our expanded research pipeline beyond core inhibitors and hepatitis B.
Bill Delaney, our Chief Scientific Officer, will be talking to you shortly about our 2 newest programs focused on HSV-2 and transplant-associated herpesviruses. And then he and I are honored to have Dr. Michael Houghton join us for the discussion. While I will introduce Dr. Houghton more formally before the Q&A session, Sir Michael needs no introduction. He is a visionary and renowned leader in virology and hepatitis, a Nobel laureate, and we're incredibly fortunate to have him on Assembly Bio's Board of Directors.
As a reminder, we'll be making forward-looking statements, so please refer to our SEC filings for a full list of disclosures.
In 2 short years, Assembly Bio has evolved from being a solely hepatitis B core inhibitor company to a virology company discovering
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)